NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SEITO Biologics AG

SEITO Biologics AG

Private
ZurichHealthcare & Life Scienceshttps://www.seitobio.ch/

Last Round

Early Funding

Jun 3, 2025

Total Funding Raised

$3.44M

Company Overview

SEITO Biologics AG is a biotechnology company that develops targeted cytokine therapies, specifically selective Treg cell engagers (TREX), to restore immune balance in patients with autoimmune and chronic-inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regulatory t cell engagersTREXimmunotherapyautoimmune diseasebiotechTreg therapychronic inflammationprecision medicinepreclinical biotechcytokine therapydrug discoverytransplant rejectionbiologic drugnext-gen immunology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SEITO Biologics AG Comparables

Compare SEITO Biologics AG with similar companies based on industry and business-model similarity.

SEITO Biologics AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Dualyx
81%
Quell Therapeutics
78%
Egle Therapeutics
77%

SEITO Biologics AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJun 3, 2025

Key People

Founding team and executive leadership

Onur Boyman

CEO, Co-Founder & Chairman

Founding Team

SEITO Biologics AG Investors

Notable investors and investment history

SEITO Biologics AG investors
InvestorRounds
Lichtsteiner FoundationEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors increased 65% MoM, reaching 1.3K.

SEITO Biologics AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SEITO Biologics AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SEITO Biologics AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersZurich
Employee Range4
Year Founded2023
Last FundingJun 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.